ERBB2 and non-small cell lung carcinoma: Zenocutuzumab, a bsAb targeting HER3 and HER2, has shown promising results, especially in disrupting HER2/HER3/NRG1 complex formation, and was recently approved by the FDA for NRG1-fusion-positive NSCLC [182].